The objective of this study was to determine the impact of modeling cancer drug wastage in economic evaluations because wastage can result from single-dose vials on account of body surface area-or weight-based dosing. METHODS: Intravenous chemotherapy drugs were identified from the pan-Canadian Oncology Drug Review (pCODR) program as of January 2015. Economic evaluations performed by drug manufacturers and pCODR were reviewed. Cost-effectiveness analyses and budget impact analyses were conducted for no-wastage and maximum-wastage scenarios (ie, the entire unused portion of the vial was discarded at each infusion). Sensitivity analyses were performed for a range of body surface areas and weights. RESULTS: Twelve drugs used for 17 indications were analyzed. Wastage was reported (ie, assumptions were explicit) in 71% of the models and was incorporated into 53% by manufacturers; this resulted in a mean incremental cost-effectiveness ratio increase of 6.1% (range, 1.3%-14.6%). pCODR reported and incorporated wastage for 59% of the models, and this resulted in a mean incremental cost-effectiveness ratio increase of 15.0% (range, 2.6%-48.2%). In the maximum-wastage scenario, there was a mean increase in the incremental cost-effectiveness ratio of 24.0% (range, 0.0%-97.2%), a mean increase in the 3-year total incremental budget costs of 26.0% (range, 0.0%-83.1%), and an increase in the 3-year total incremental drug budget cost of approximately CaD $102 million nationally. Changing the mean body surface area or body weight caused 45% of the drugs to have a change in the vial size and/or quantity, and this resulted in increased drug costs. CONCLUSIONS: Cancer drug wastage can increase drug costs but is not uniformly modeled in economic evaluations. Cancer 2017;123:3583-90.
INTRODUCTION
The rising costs of cancer care pose a substantial financial burden for the health-care system. 1 In the United States, spending on cancer care is expected to increase to $158 billion in 2020 (a 27% increase from 2010). 2 In particular, the growing costs of novel anticancer drugs are concerning. 3 From 1995 to 2013, the average launch price of anticancer drugs increased by 10% or an average of $8500 annually after adjustments for inflation and health benefits. 4 Increasing drug costs have prompted the need for a critical evaluation regarding their value. 5 The value of cancer treatments can be assessed with a framework developed by the American Society of Clinical Oncology that takes the clinical benefits, toxicities, and treatment costs into account. 6 Cost-effectiveness analyses are commonly used to evaluate the potential costs and benefits of health interventions. However, they are often conducted under the assumption of no drug wastage, which does not reflect real-world clinical practice. The administration of intravenous drugs from single-dose packages may cause wastage because of body surface area-or weight-based dosing. Because of variable patient body sizes, the amount of the drug that is required may not match the amount of the drug in the vial, and this results in leftover drug, which is discarded. Limited vial size options and drug stability restrict the potential of vial sharing between patients. 7 Drug wastage results in incremental costs without incremental value to patients. For example, a single institutional study in Canada showed that wastage of azacitidine resulted in an additional $150,000 in annual drug costs. 8 A recent study by Bach et al 9 has shown that oversized vials of chemotherapy drugs can result in substantial wastage and costs. 10 The top 20 anticancer drugs in 2016 were analyzed, and it was estimated that 10% of the $18 billion revenue resulted from wasted drugs. 9 Furthermore, a systematic review showed that the incorporation of wastage into economic evaluations could markedly affect the incremental cost-effectiveness ratios of intravenous drugs for hematological malignancies. 11 In clinical practice, strategies have been developed to reduce wastage, including batching patients to facilitate vial sharing, reusing single-dose vials, and dose banding. 12 However, these strategies may not be feasible for implementation at smaller centers and for rare diseases.
In Canada, the pan-Canadian Oncology Drug Review (pCODR), a program of the Canadian Agency for Drugs and Technologies in Health, provides recommendations about which drugs to publicly reimburse by reviewing clinical and economic evidence. Drug manufacturers submit economic evaluations that are reviewed and re-analyzed by the pCODR's economic guidance panel (EGP) to ensure that the costs and benefits of a drug are accurately captured while minimizing uncertainty and the risk of bias. 13 There is considerable potential for drug wastage to affect economic evaluations, but there is a lack of guidance for modeling wastage. We sought to determine the impact of modeling cancer drug wastage on the results of economic evaluations. We reviewed cost-effectiveness analyses and budget impact analyses provided by the manufacturers and the EGP and conducted an independent analysis to evaluate wastage modeling and its impact on incremental costeffectiveness ratios and incremental budget costs. We also analyzed the impact of the mean body surface area and body weight chosen for modeling on economic evaluations because changes in these parameters might affect the quantity and/or size of the vials used.
MATERIALS AND METHODS
Recently approved intravenous chemotherapy drugs (as of January 2015) were identified from the pCODR section of the Canadian Agency for Drugs and Technologies in Health Web site. 14 We reviewed the cost-effectiveness analyses and budget impact (re-)analyses submitted by the manufacturers and the EGP. The cancer type, indications, listed price, vial size availability, drug stability, recommended starting dose, incremental cost-effectiveness ratios, and incremental budget costs submitted by both the manufacturers and the EGP were recorded. We conducted an independent analysis for the no-wastage and maximum-wastage scenarios. The primary outcomes were the impact of wastage on the incremental costeffectiveness ratios and the 3-year total incremental budget costs. For budget impact analyses that were evaluated from a provincial perspective rather than a national perspective, we scaled up the analysis by dividing the 3-year total incremental budget costs by the population of the province and multiplying that by the population of Canada according to the most recent Canadian census. 15 Drug submissions were reviewed for the reporting and incorporation of wastage in the manufacturer and EGP base-case and/or sensitivity (re-)analyses. Reporting refers to explicitly stating whether wastage was modeled. When wastage was not reported by either the manufacturer or the EGP, it was assumed that wastage was not incorporated into the model.
We analyzed the following scenarios in our independent analysis: 1) no wastage based on the cost per milligram of drug and 2) maximum wastage based on the cost per vial under the assumption that the entire unused portion is discarded after each infusion (Supporting Material 1 [see online supporting information]). The mean body surface area or body weight from the manufacturer's economic model was multiplied by the recommended starting dosage (Supporting Material 2 [see online supporting information]) to determine the required dose per infusion. The amount of drug wastage per infusion was calculated by the subtraction of the required dose per infusion from the total amount of drug in the smallest vial and minimum number of combined vials needed to achieve the required dose per infusion. The amount of drug wasted per infusion was then divided by the smallest vial used to determine the proportion of drug wasted per vial. The percentage change in the drug cost per cycle with the cost per vial versus the cost per milligram of the drug was calculated. The cost per cycle in the no-wastage scenario was determined by multiplication of the cost per milligram of the drug by the dose per infusion and the number of infusions in a cycle. The cost per cycle in the maximum-wastage scenario was determined by multiplication of the cost per vial by the number of vials needed per infusion and the number of infusions per cycle. The required number of vials was determined by the combination of the smallest vial and the minimum number of vials needed to achieve the required dose at each infusion. We conducted our analysis with executable Excel-based economic models submitted by the drug manufacturers. We calculated the percentage change in the incremental costeffectiveness ratio and the 3-year total incremental budget costs to compare the (maximum-) wastage and nowastage scenarios. To assess the impact of the manufacturer's choice of body surface area and body weight in Original Article these economic models, these variables were increased in increments of 0.5 mg/m 2 between 1.7 and 1.9 mg/m 2 and in increments of 5 kg between 70 and 90 kg, respectively.
RESULTS
In total, 12 intravenous drugs used for 17 indications were included in the analysis ( Table 1) . Four of these drugs were for the treatment of hematological malignancies, and 8 of these drugs were for the treatment of solid tumors.
Reporting and Incorporation of Wastage in Economic Models by the Manufacturer and the EGP
Drug wastage assumptions were reported by the manufacturer in 71% of the models (12 of 17), and wastage was incorporated in 53% of the models (9 of 17; Supporting Material 3 [see online supporting information]). Wastage was assumed in 3 base-case analyses (ie, brentuximab vedotin for Hodgkin's lymphoma, ipilimumab, and trastuzumab emtansine), and sensitivity analyses assuming no wastage were further conducted for ipilimumab and trastuzumab emtansine indications. The manufacturer submissions included sensitivity analyses assuming wastage for 6 drug indications. No wastage was assumed for 3 drug indications (ie, bendamustine for first-line chronic lymphocytic leukemia, brentuximab vedotin for systemic anaplastic large cell lymphoma, and pertuzumab) for both base-case and sensitivity analyses.
The pCODR EGP reported wastage assumptions and incorporated wastage into its re-analyses for 59% of the intravenous drug indications (10 of 17; Supporting Material 3 [see online supporting information]). The EGP re-analyzed the effects of wastage provided by the manufacturer for 8 drug indications. In addition, the EGP conducted wastage analyses for 2 drug indications that were not provided by the manufacturer (ie, bortezomib and brentuximab vedotin for systemic anaplastic large cell lymphoma).
Impact of Wastage on Drug Costs per Cycle
The drug costs per cycle for the no-wastage and maximum-wastage scenarios normalized to a 28-day cycle were calculated for intravenous chemotherapies ( Table 2 ). The average proportion of drug wasted from the smallest vial was 45.6% (range, 0.0%-87.5%) per infusion. The average amount of drug wasted was 72.0 mg (range, 0.0-300.0 mg) per cycle. Wastage increased drug costs per cycle by a mean of 21.8% (range, 0.0%-77.8%).
Arsenic trioxide for induction treatment in acute promyelocytic leukemia had the greatest percentage increase in drug costs when wastage was analyzed. In the induction phase, the recommended starting dose of arsenic trioxide is 0.15 mg/kg per day. If maximum wastage is assumed for a 75-kg patient, a 78% increase in drug costs will arise, and this translates into increased incremental cost-effectiveness ratios of 71.4% and 97.2% in the firstline and relapsed/refractory settings, respectively. Similarly, the 3-year total incremental budget cost will increase by 78.4% and 83.1%, respectively. Table 3 shows the percentage difference in the wastage and no-wastage scenarios for the incremental costeffectiveness ratios provided by the manufacturers and the EGP as well as our independent analysis. It also shows the percentage differences in the maximum-wastage and nowastage scenarios for our calculated 3-year total incremental costs.
Wastage increased the manufacturers' incremental cost-effectiveness ratios for the 8 drug indications by a mean of 6.1% (range, 1.3%-14.6%). Aflibercept had the greatest increase, whereas bendamustine for nonHodgkin lymphoma had the smallest increase. The incremental cost-effectiveness ratio for ipilimumab increased by 10.5% in comparison with dacarbazine and converted ipilimumab dominance to $10,776 per quality-adjusted life year gained in comparison with vemurafenib.
The EGP provided wastage incremental costeffectiveness ratios for 5 drug indications (Table 3) . Wastage increased EGP's incremental cost-effectiveness ratios by a mean of 15.0% (range, 2.6%-48.2%). Wastage had the largest effect on bortezomib for induction and the least effect on arsenic trioxide in the relapsed/refractory setting. For the remaining drugs, the effects of wastage were provided in aggregate with other modified factors (eg, the time horizon) and could not be isolated.
Wastage increased our calculated incremental costeffectiveness ratios by a mean of 24.0% (range, 0.0%-97.2%) and increased the 3-year total incremental budget costs by a mean of 26.0% (range, 0.0%-83.1%). Over a 3-year period, our analysis shows that wastage can increase the total incremental budget costs by approximately CaD $102 million from a national perspective for the 17 drugs (Table 3) .
Impact of the Mean Body Surface Area and Body Weight on Economic Evaluations
The percentage changes in drug costs due to wastage over a range of mean body surface areas and body weights are shown in Supporting Material 4 (see online supporting information). Forty-five percent of the drug indications/ settings (9 of 20) required a change in vial size or quantity over these ranges. Under the assumption that the mean body surface area is 1.8 mg/m 2 and that the mean body weight is 75 kg, the average percentage increase in drug costs due to wastage is 18.9% and 26.1%, respectively. The changes in drug costs per cycle due to wastage over the specified ranges of body surface areas and body weights are shown in Figures 1 and 2 , respectively. The percentage increase in drug costs over this specific mean body surface area series (Fig. 1 ) had a range of 0.0% to 56.7%, whereas the specific mean body weight series (Fig.  2) had a range of 0.0% to 84.4%. Substantial increases in drug costs related to wastage due to changes in vial size or quantity can occur. For example, brentuximab (available in 50-mg vials) had a 4.5% increase at 80 kg; this rose to 35.4% at 85 kg despite a modest increase from 144 to 154 mg per dose required per infusion.
DISCUSSION
In our analysis, more than two-thirds of the models reported wastage assumptions, and half of them incorporated wastage into their base-case or sensitivity analyses. Our analysis shows that wastage increases the incremental cost-effectiveness ratios by a mean of 24.0%, which is higher than the values suggested by the manufacturers (6.1%) and the EGP (15.0%). This is likely due to differences in the assumption of drug wastage because some models assumed partial wastage, whereas we Abbreviations: APL, acute promyelocytic leukemia; BR, bendamustine and rituximab; BSC, best supportive care; CLL, chronic lymphocytic leukemia; EGP, economic guidance panel; HL, Hodgkin's lymphoma; ICER, incremental cost-effectiveness ratio; iNHL, indolent non-Hodgkin lymphoma; mBC, metastatic breast cancer; MCL, mantle cell lymphoma; mCRC, metastatic colorectal cancer; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab with cyclophosphamide, vincristine, and prednisolone; RR, relapsed/refractory; sALCL, systemic anaplastic large cell lymphoma. This table shows the percentage differences in ICERs and 3-year total incremental costs for the wastage and no-wastage scenarios from the manufacturer, EGP, and independent calculations. a These ICERs were calculated from the available incremental costs and quality-adjusted life-years for no-wastage and wastage scenarios because the ICERs were not provided.
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Cancer September 15, 2017 assumed maximum wastage. In comparison, a previous systematic review by Lien et al 7 reported that only 32% of 38 published intravenous drug models for malignancies considered wastage in their base-case analyses, and only 2 of these conducted further sensitivity analyses in which no wastage was assumed. Fewer economic models incorporated wastage in comparison with our current study. However, their study documented a similar impact of the incorporation of wastage; modeling for wastage resulted in an increase in the incremental costeffectiveness ratio of 32% for 1 drug model and caused azacitidine to dominate decitabine even though azacitidine had an incremental cost-effectiveness ratio of $15,528 per quality-adjusted life year when no wastage was assumed.
A recent study by Bach et al 9 highlights the need to examine drug wastage. For example, they found that bortezomib, indicated for multiple myeloma, is available only in 3.5-mg vials in the United States, whereas 1-mg vials are available in the United Kingdom. They estimated that 27% to 30% of bortezomib sales in the United States are associated with wasted drug. A retrospective study of bortezomib usage in Brazil showed that the average dose was 2.1 mg, and this resulted in 39.5% of the vial being wasted. 16 The authors also showed that alternative vial sizes for bortezomib could reduce wastage by 62%. In our analysis, the average dose was 2.28 mg per infusion, and this resulted in 35.0% of the vial being wasted. Wastage increased drug costs by 53.8% per cycle. Clearly, there is a need to address the wastage associated with the limited range of vial sizes. Bach et al suggested that policymakers require that manufacturers either package drugs in a variety of sizes that minimize wastage or refund the cost of the leftover drugs. Further research into disease-specific body surface areas and weights may help to elucidate the ideal vial size options to minimize drug wastage. Guidelines (eg, wastage cannot exceed a certain percentage of the vial size for the average patient body surface area or weight as determined from disease-specific population data) can be used to encourage pharmaceutical companies to package drugs in sizes that do not promote excessive wastage.
Several cancer drug cost-saving strategies, including the rounding of doses, dose banding, vial sharing, and multidose vials, have been studied. A single center found that wastage was responsible for 8.3% of total intravenous drug costs, but this could be reduced by half by the implementation of protocols that include rounding up doses within 5% of the calculated dose and the selection of optimal vial sizes with chemical stability for up to 24 hours. 17 At another institution, dose rounding within 10% was found to potentially reduce 42% of wastage without any detrimental effects on efficacy. 18 Dose banding entails predefining a set of body surface area ranges and selecting a value per band to calculate the required dose. 12 If dose banding is conducted within a 5% tolerance limit, there is no significant change to the administered dose. 19 In addition, the sharing of vials between patients can be used to reduce costs, but this is limited to relatively large centers. 19 A 2-year retrospective study at a single institution has shown that vial sharing for cytotoxic drugs is costeffective, especially with a 7-day vial-sharing practice. 20 However, the financial benefits are limited to specific drugs because some high-cost, low-volume drugs are associated with additional costs with this vial-sharing method. 20 Finally, multidose vials or the reuse of singledose vials may alleviate wastage, but there are concerns regarding their safety. There have been several reports of outbreaks associated with multidose vials that resulted in death. 21, 22 In addition, when the administration of peginesatide was switched from single-use vials to multipleuse vials, several cases of fatal anaphylaxis occurred. 23 Furthermore, US Pharmacopeia chapter 797, which sets the standards for sterile preparations of pharmaceutical compounding, makes vial sharing and multidose vials impractical. 24 The potential for intravenous drugs to be shared or reused is limited not only by their chemical stability: US Pharmacopeia chapter 797 also recognizes the importance of microbiological limits. 25 Despite adherence to strict sterile guidelines, drugs can become contaminated during preparation.
The conventional method of modeling wastage is to assume a fixed mean body surface area or body weight to calculate the dose needed. However, if these parameters are chosen to minimize the number and/or size of vials, it may lead to a falsely low impact of wastage on costs in the real world. There is also heterogeneity in the sources used to select the body surface area or body weight because there are no standard values for economic appraisal. 19 Furthermore, the practice of using a single fixed mean body surface area or body weight ignores the full range of values in a population. Our analysis (Supporting Material 4 [see online supporting information]) shows that this parameter does affect the impact of wastage on costs, incremental cost-effectiveness ratios, and budgets.
The comprehensiveness of this study was ensured by collaboration with the pCODR program to obtain source disclosable information for all novel cancer drugs being considered for funding. Thus, our data reflect current practices, which show the inconsistency of wastage considerations in economic models. However, there may be limitations in translation to the real world, where vial-sharing practices occur at different rates according to the standard operating procedures at individual institutions.
In conclusion, wastage can have significant impacts on economic evaluations of intravenous chemotherapy drugs. Drug wastage incurs costs without providing value to patients. This issue remains underrecognized despite a considerable potential impact on incremental costeffectiveness ratios and incremental budget costs. 26 The variation in wastage modeling suggests that guidelines are needed to promote uniform and optimal modeling of drug wastage in economic evaluations. Drug wastage is driven by large vial sizes and restricted packaging options; policymakers should encourage pharmaceutical companies to increase vial size options or refund the amount of drug wasted. The amount of drug wasted and drug costs are affected by the mean body surface area or body weight that is chosen for the economic model. Future economic evaluations should consistently incorporate wastage and should also conduct sensitivity analyses for the full range of body surface areas and body weights in the population.
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